KR102357699B1 - 발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법 - Google Patents

발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법 Download PDF

Info

Publication number
KR102357699B1
KR102357699B1 KR1020167014876A KR20167014876A KR102357699B1 KR 102357699 B1 KR102357699 B1 KR 102357699B1 KR 1020167014876 A KR1020167014876 A KR 1020167014876A KR 20167014876 A KR20167014876 A KR 20167014876A KR 102357699 B1 KR102357699 B1 KR 102357699B1
Authority
KR
South Korea
Prior art keywords
dna
synthetic
artificial sequence
gene
genbank accession
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167014876A
Other languages
English (en)
Korean (ko)
Other versions
KR20160127713A (ko
Inventor
루이스 엠 스타우트
조지 더블유 라이트
데이빗 윌리엄 스콧
조셉 엠 콘노르스
랜디 디 가스코인
리사 림자
게리 엘리아스 캄포
레이몬드(사망) 튜브스
티모시 씨 그레이너
제임스 로버트 쿡
카이 푸
폴 마이클 윌리엄스
치-지안 리
엘라인 에스 자페
리타 엠 브라지엘
안드레아스 로젠발트
얼렌드 비 스멜란드
윙 씨 찬
게르만 오트
얀 델라비
데니스 와이센버거
Original Assignee
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
브리티쉬 콜롬비아 캔써 에이전시 브랜치
아리조나 보드 오브 리전츠 온 비해프 오브 유니버시티 오브 아리조나
유니버시테이트 드 바르셀로나
호스피탈 크리닉 드 바르셀로나
더 클리블랜드 클리닉 파운데이션
보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카
오레곤 헬스 앤드 사이언스 유니버시티
율리우스-막시밀리안스 우니버지태트 뷔르츠부르크
오슬로 유니버시티 하스피탈 에이치에프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈, 브리티쉬 콜롬비아 캔써 에이전시 브랜치, 아리조나 보드 오브 리전츠 온 비해프 오브 유니버시티 오브 아리조나, 유니버시테이트 드 바르셀로나, 호스피탈 크리닉 드 바르셀로나, 더 클리블랜드 클리닉 파운데이션, 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카, 오레곤 헬스 앤드 사이언스 유니버시티, 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크, 오슬로 유니버시티 하스피탈 에이치에프 filed Critical 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Publication of KR20160127713A publication Critical patent/KR20160127713A/ko
Application granted granted Critical
Publication of KR102357699B1 publication Critical patent/KR102357699B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020167014876A 2013-11-06 2014-11-05 발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법 Active KR102357699B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900553P 2013-11-06 2013-11-06
US61/900,553 2013-11-06
PCT/US2014/064161 WO2015069790A1 (en) 2013-11-06 2014-11-05 Method for subtyping lymphoma types by means expression profiling

Publications (2)

Publication Number Publication Date
KR20160127713A KR20160127713A (ko) 2016-11-04
KR102357699B1 true KR102357699B1 (ko) 2022-02-04

Family

ID=51987470

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167014876A Active KR102357699B1 (ko) 2013-11-06 2014-11-05 발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법

Country Status (9)

Country Link
US (2) US10607717B2 (https=)
EP (2) EP3594359B1 (https=)
JP (2) JP6657105B2 (https=)
KR (1) KR102357699B1 (https=)
CN (1) CN106232831B (https=)
AU (1) AU2014346788B8 (https=)
CA (1) CA2929826C (https=)
ES (2) ES2738289T3 (https=)
WO (1) WO2015069790A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
US20240430385A1 (en) * 2015-04-16 2024-12-26 Offender Smartphone Monitoring, LLC Monitoring process
WO2016168667A1 (en) * 2015-04-16 2016-10-20 Offender Smartphone Monitoring, LLC Monitoring process
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
CN108368554B (zh) * 2015-09-29 2022-09-09 Htg分子诊断有限公司 弥漫性大b细胞淋巴瘤(dlbcl)亚型分型的方法
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
JP7075896B2 (ja) * 2016-04-20 2022-05-26 アメリカ合衆国 マントル細胞リンパ腫の評価及びそれに関連する方法
US9963748B2 (en) 2016-05-13 2018-05-08 Roche Molecular Systems, Inc. Methods and compositions for classifying DLBCL
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
US11696250B2 (en) * 2016-11-09 2023-07-04 Intel Corporation UE and devices for detach handling
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
EP3638814B8 (en) 2017-06-14 2023-06-21 The United States of America, as Represented by The Secretary, Department of Health and Human Services Method for determining lymphoma type
ES2933256T3 (es) * 2017-08-08 2023-02-03 Hoffmann La Roche Tratamiento con obinutuzumab de un subgrupo de pacientes con LDLBG
JP7517983B2 (ja) * 2017-11-20 2024-07-17 ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク 非常に低レベルのｃｄ１９を発現する骨髄腫細胞を除去するｃｄ１９ｃａｒｔ細胞
CN110945130B (zh) 2017-12-01 2024-04-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7365052B2 (ja) 2017-12-01 2023-10-19 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
CA3083968C (en) 2017-12-01 2024-04-23 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
WO2019105437A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105435A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
EP3732185B1 (en) 2017-12-29 2025-02-26 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
WO2020028563A1 (en) * 2018-08-01 2020-02-06 Genentech, Inc. Prediction and characterization of dlbcl cell of origin subtypes
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020079591A1 (en) * 2018-10-15 2020-04-23 Provincial Health Services Authority Gene expression profiles for b-cell lymphoma and uses thereof
MX2021005646A (es) * 2018-11-14 2021-08-11 Beyondspring Pharmaceuticals Inc Métodos de tratamiento de cáncer con agentes de unión a tubulina.
US12496347B2 (en) 2018-12-28 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
AU2020245086B2 (en) * 2019-03-28 2026-01-08 Centre Henri Becquerel Classification of B-Cell non-Hodgkin Lymphomas
CN111850114A (zh) * 2019-04-25 2020-10-30 上海交通大学医学院附属瑞金医院 一组用于评估弥漫大b细胞淋巴瘤分子分型的基因群，其试剂盒及分析方法
WO2020233651A1 (zh) * 2019-05-22 2020-11-26 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
JP7610268B2 (ja) 2019-05-22 2025-01-08 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
WO2020233680A1 (zh) 2019-05-22 2020-11-26 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
AU2020280438B2 (en) 2019-05-22 2025-03-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
EP3978609A4 (en) 2019-05-24 2024-02-07 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
EP4682889A3 (en) * 2019-07-22 2026-04-15 F. Hoffmann-La Roche AG Systems and methods for cell of origin determination from variant calling data
MX2022001812A (es) 2019-08-12 2022-03-11 Regeneron Pharma Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos.
CN111621565B (zh) * 2020-05-07 2023-12-15 杭州可帮基因科技有限公司 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置
CN111785370B (zh) * 2020-07-01 2024-05-17 医渡云（北京）技术有限公司 病历数据处理方法及装置、计算机存储介质、电子设备
CN115955962B (zh) * 2020-07-08 2024-07-12 代顿治疗股份公司 用于治疗淋巴肿瘤的沙铂
JP2023536900A (ja) * 2020-08-05 2023-08-30 ティアークリアー コープ． 眼科用製剤からの防腐剤除去のためのシステムおよび方法
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN113186289B (zh) * 2021-05-12 2023-02-24 清华大学深圳国际研究生院 lncRNA在肾癌尿液筛查和肾癌治疗中的应用
CN119842823A (zh) * 2024-12-25 2025-04-18 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） SLC35E2B在Hacat细胞模型构建中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005024043A2 (en) 2003-09-03 2005-03-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
WO2009149359A2 (en) 2008-06-06 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Survival predictor for diffuse large b cell lymphoma

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
JP2001524926A (ja) 1991-09-18 2001-12-04 アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ オリゴマーの雑多ライブラリーの集合体を合成する方法
US5550215A (en) 1991-11-22 1996-08-27 Holmes; Christopher P. Polymer reversal on solid surfaces
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
DE69233501T2 (de) 1991-11-22 2006-02-23 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Kombinatorische Strategien für die Polymersynthese
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
WO1995030774A1 (en) 1994-05-05 1995-11-16 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
WO1997043611A1 (en) 1996-05-16 1997-11-20 Affymetrix, Inc. Systems and methods for detection of labeled materials
EP1027456B1 (en) 1997-10-31 2005-03-16 Affymetrix, Inc. (a Delaware Corporation) Expression profiles in adult and fetal organs
US5936324A (en) 1998-03-30 1999-08-10 Genetic Microsystems Inc. Moving magnet scanner
US6020198A (en) 1998-09-25 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of RIP-1 expression
US7105293B2 (en) 2000-09-19 2006-09-12 Whitehead Institute For Biomedical Research Genetic markers for tumors
US20030194701A1 (en) 2000-11-20 2003-10-16 Golub Todd R. Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
CN1273465C (zh) 2001-09-21 2006-09-06 保宁制药株式会社 嘧啶酮化合物及其药学上可接受的盐的制备方法
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
ES2542328T3 (es) 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
NZ585188A (en) 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US20110152115A1 (en) 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
US8131475B2 (en) * 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
ATE514434T1 (de) 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
EP1805197A1 (en) 2004-09-27 2007-07-11 Med Biogene Inc Hematological cancer profiling system
US8349555B2 (en) 2005-03-16 2013-01-08 Gennadi V. Glinsky Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
MX2010005080A (es) * 2007-11-07 2010-07-28 Genentech Inc Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
EP2245199B1 (en) * 2008-02-01 2013-11-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
BR112012001077A2 (pt) 2009-07-16 2020-08-11 The General Hospital Corporation extração de ácido nucleico, métodos para avaliar a qualidade de uma extração de ácido nucleico e de uma amostra biológica, para ober ácido nucleico a partir de uma amostra biológica, para analisar rna de microvesículas e para diagnosticar e monitorar um indivíduo, e, kit
ES2352777B1 (es) 2009-07-31 2012-01-23 Hospital Clinic De Barcelona Metodo y kit para el pronostico del linfoma de celulas del manto
WO2011060272A2 (en) * 2009-11-13 2011-05-19 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
WO2011097476A1 (en) * 2010-02-04 2011-08-11 Indiana University Research And Technology Corporation 4-protein biomarker panel for the diagnosis of lymphoma from biospecimen
EP2569335B1 (en) * 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
CN107898791A (zh) * 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
US20120258878A1 (en) 2010-08-04 2012-10-11 Med Biogene Inc. Prognostic gene signatures for non-small cell lung cancer
CA2834535A1 (en) 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
CA2858383A1 (en) 2011-12-09 2013-06-13 British Columbia Cancer Agency Branch Predicting prognosis in classic hodgkin lymphoma
JP2015509489A (ja) 2012-02-10 2015-03-30 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ がんの処置のためのグリシン開裂系の阻害
US9803245B2 (en) 2012-03-14 2017-10-31 University Health Network Signature for predicting clinical outcome in human HER2+ breast cancer
WO2013188600A1 (en) 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
WO2014197936A1 (en) 2013-06-14 2014-12-18 The State Of Queensland Acting Through Its Department Of Health Biomarkers and use thereof in identification of b-cell lymphoproliferative disorders
IL278381B2 (en) 2013-12-06 2024-08-01 Celgene Corp Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005024043A2 (en) 2003-09-03 2005-03-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
US20050164231A1 (en) 2003-09-03 2005-07-28 Staudt Louis M. Methods for identifying, diagnosing, and predicting survival of lymphomas
WO2009149359A2 (en) 2008-06-06 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Survival predictor for diffuse large b cell lymphoma

Also Published As

Publication number Publication date
ES2738289T3 (es) 2020-01-21
EP3594359A1 (en) 2020-01-15
EP3066215A1 (en) 2016-09-14
JP7016129B2 (ja) 2022-02-04
ES2923942T3 (es) 2022-10-03
KR20160127713A (ko) 2016-11-04
AU2014346788B2 (en) 2020-09-24
EP3066215B1 (en) 2019-04-24
US20200143906A1 (en) 2020-05-07
WO2015069790A1 (en) 2015-05-14
JP6657105B2 (ja) 2020-03-04
CA2929826C (en) 2022-08-16
CN106232831B (zh) 2021-02-26
US10607717B2 (en) 2020-03-31
AU2014346788B8 (en) 2021-01-28
EP3594359B1 (en) 2022-05-18
WO2015069790A9 (en) 2016-06-02
JP2020078323A (ja) 2020-05-28
US11574704B2 (en) 2023-02-07
JP2017502686A (ja) 2017-01-26
AU2014346788A8 (en) 2016-06-16
CN106232831A (zh) 2016-12-14
US20160283653A1 (en) 2016-09-29
CA2929826A1 (en) 2015-05-14
AU2014346788A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
KR102357699B1 (ko) 발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법
AU2016331663B2 (en) Pathogen biomarkers and uses therefor
AU2018210695B2 (en) Molecular subtyping, prognosis, and treatment of bladder cancer
CN107941681B (zh) 鉴定生物样品中定量细胞组成的方法
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
DK2644713T3 (en) A Method for Diagnosing Neoplasms II
RU2721916C2 (ru) Способы прогнозирования рака предстательной железы
KR101421326B1 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
KR100964193B1 (ko) 간암 예후 마커
CN101573453A (zh) 使用生物学途径基因表达分析来预测淋巴结阴性原发性乳腺癌的远处转移的方法
JP2003304888A (ja) 化合物の毒性予測のための方法
CN101258249A (zh) 检测黑素瘤的方法和试剂
AU2008203226A1 (en) Colorectal cancer prognostics
AU2016377391B2 (en) Triage biomarkers and uses therefor
KR20040065524A (ko) 백혈병을 검사 및 치료하는 방법
DK3201630T3 (en) Multiplex assay for simultaneous detection of TP53 / CEN17 / B cell gene protein and uniquely specific probes for 19Q12, INSR, ATM, DLEU2, TP53 and 13Q12
KR20060045950A (ko) 혈액학적 악성종양에 대한 예후
US20020137077A1 (en) Genes regulated in activated T cells
AU2016349950B2 (en) Viral biomarkers and uses therefor
KR20070099564A (ko) 급성 골수성 백혈병 환자를 평가하는 방법
KR101128112B1 (ko) 결장 직장암의 예후 진단법
CN101111768A (zh) 肺癌预后
KR102480128B1 (ko) 면역력 강화 소 African Humped Cattle (AFH) 품종 특이적 단일염기다형성 및 그의 용도
CN108779496B (zh) 罹患食管基底细胞样鳞状细胞癌的鉴别方法
KR102480121B1 (ko) 수면병 저항성 소 African taurine cattle (AFT) 품종 특이적 단일염기다형성 및 그의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4